减量CTOP方案治疗高龄非霍奇金淋巴瘤的临床观察  

Clinical observation of reduced CTOP regimen in the treatment of 11 elderly patients with non-Hodgkin′s lymphoma

作　　者：李秀梅[1] 庄万传[1] 韩秀华[1] 何耀[1] 

机构地区：[1]江苏省连云港市第二人民医院血液科,连云港222023

出　　处：《药学与临床研究》2007年第6期468-470,共3页Pharmaceutical and Clinical Research

摘　　要：目的：探讨高龄中、高度恶性非霍奇金淋巴瘤的治疗手段、疗效，以及治疗产生的相关毒副作用。方法：11例高龄中、高度恶性非霍奇金淋巴瘤患者（〉80岁），采用减量CTOP方案化疗4—8个周期，观察其临床症状、体征，并监测血常规、血生化、心电图等。结果：11例患者中，完全缓解（CR）6例，部分缓解（PR）3例，总反应率（CR＋PR）81．8％，常见副作用为肺部感染、白细胞减少等，但均未影响化疗。结论：高龄非霍奇金淋巴瘤患者采用减量CTOP方案治疗可获得较满意疗效，且副作用轻微，可进一步临床应用观察。Objective：To explore the efficacy and toxicity of the treatment of very elderly patients with aggressive non-Hodgkin＇s lymphoma. Methods： 11 very elderly patients（ 〉 80 years） with aggressive non-Hodgkin＇s lymphoma received 4 - 8 cycles of reduced CTOP regimen, and were observed the curative effects and adverse events. Results： Among 11 patients, 6 patients acquired complete remission, 3 patients acquired partial remission, the overall response rate was 81.8%. Side effects were slight-mainly pulmonary infections and leucopenia, which didn＇t interrupt the chemical therapies. Conclusion： Very elderly patients with aggressive non-Hodgkin＇s lymphoma, who treated with reduced CTOP regimen, could acquired good curative effects, and the side effects were light. The reduced CTOP regimen is worthy of further research.

关 键 词：高龄 非霍奇金淋巴瘤 减量CTOP方案 

分 类 号：R969.4[医药卫生—药理学]